Background {#Sec1}
==========

Breast cancer is the most common malignant tumor in women worldwide, comprising 16 % of all female cancers. Epidemiological studies have shown that vitamin E has a potential utility in the prevention and treatment of human malignancies, including breast cancer \[[@CR1]--[@CR3]\]. However clinical trials on the effectiveness of dietary supplementation with vitamin E or *α-*tocopherol, the principle and most active vitamin E isoform in human plasma, as an aid in the prevention of cancer have not produced evidence of a consistent association with decreased cancer occurrence \[[@CR4], [@CR5]\]. The inconstancies between epidemiological studies and intervention trials may be due to differing roles for the tocopherols that comprise vitamin E or unexplained genetic diversity in the study populations affecting how they utilized vitamin E.

Our previous studies have shown that *α-*Tocopherol-associated protein (TAP), a vitamin E binding protein \[[@CR6]\], is selectively expressed in human breast, prostate, liver and brain tissue and its expression can be evaluated by immunohistochemical staining \[[@CR7], [@CR8]\]. We have shown that, while TAP can facilitate vitamin E retention in cancer cells and promote vitamin E-mediated anti-proliferation effects, it can also act as a tumor suppressor-like protein in a vitamin E-independent fashion. Overexpression of TAP in prostate cancer cells was shown to suppress cell growth; and a TAP siRNA knockdown in a prostate cell line led to increased cell growth \[[@CR7]\]. In human breast, we identified that TAP is typically co-expressed with ER in sporadic normal/benign luminal cells in terminal ductal lobular units, and that TAP showed decreased expression in 57 % of invasive breast carcinomas, including 46 % of ER and PR positive carcinomas, and 80 % of high grade carcinomas \[[@CR9]\]. Another study has shown that TAP mRNA level is negatively associated with tumor stage and lymph node status in breast cancer \[[@CR10]\]. TAP expression therefore may be a candidate for a marker of less aggressive breast carcinoma.

Despite the advances in multidisciplinary treatment, breast cancer remains the second most common cause of death related to cancer in women. In addition to the routine pathologic characteristics of breast cancer, such as tumor size, grade, vascular invasion, lymph node metastasis, ER/PR/Her2 status etc., genes which may have an association with tumor biology and help in predicting recurrence, therapeutic response and survival have been studied widely. Currently there are at least nine gene expression signatures showing some correlation with certain clinical breast cancer outcomes \[[@CR11]--[@CR16]\]. The genes included in these panels are diverse but largely related to cell cycle regulation and proliferation, the ER pathway, and to a lesser degree, the immune system. Although these gene panels have similar outcomes performance, they exhibit a large degree of discordance in the assignment of a particular breast tumor to a specific prognostic group \[[@CR11]\]. More accurate prognostic predictive gene signatures will depend on better understanding of the genes specifically involved in breast cancer carcinogenesis.

To further investigate if TAP expression is associated with clinical outcome in breast carcinomas, we studied TAP expression in a breast cancer cohort of 271 patients diagnosed with invasive breast carcinomas with median follow up time of 5.2 years. In addition, in an independent cohort of 71 breast cancer cases, we compared TAP expression with the Oncotype DX recurrence score to determine if there was a correlation between TAP expression and this clinically available multigene prognostic/predictive assay.

Methods {#Sec2}
=======

A tissue micro-array comprising 288 patient samples from a primary invasive breast cancer cohort from the Clearview Cancer Institute (CCI, AL, U.S.A.), consisting of all available patient samples collected from 1990 to 2001, was constructed. The patient average age was 58.9 (range 26--89), with an average tumor size 2.21 cm (range 0.2--8.0) and a median follow up time of 5.2 years. Ninety eight tumors were stage 1, 141 stage 2, and 33 stage 3. One hundred fifty four patients had negative lymph nodes, while 118 patients had positive lymph node(s). One hundred thirty two patients had received chemotherapy plus hormonal therapy, while 156 were untreated or treated with hormonal therapy only. No patients had been treated with Herceptin. Thirty six tumors were grade 1, 106 were grade 2 and 93 were grade 3. Within this cohort, 271 patients had complete follow-up and TAP expression data. The composition of this set of patients is as shown in Table [1](#Tab1){ref-type="table"}.Table 1Cohort characteristics. *P* value for difference between proportion of clinical characteristic within TAP positive and negative patients determined with a two-proportion z-test, except for age and tumor size for which a *t*-test was employedAll casesTAP negativeTAP positiveNo. of patients%No. of patients%No. of patients%*P* valueTotal27118388Grade 13412.52010.91415.90.33 210538.75932.24652.30.02 39233.97842.61415.90.03 Unknown4014.82614.21415.9ndStage I9735.86032.837420.18 II13750.69451.44348.90.39 III3111.42312.689.10.4 Unknown62.263.30ndAge (avg, range)58.1 (26--89)56.9 (26--87)62.6 (35--89)\<0.001T T113850.98244.85663.60.01 T210137.37440.42730.70.19 T3145.2126.622.30.41 T48363.322.30.47 Unknown103.794.911.1ndN N015055.497535360.20.2 N110839.97440.43438.60.43 N262.252.711.10.46 Unknown72.673.80ndM M025899.217298.9861001 M120.821.10nd Unknown1192ndTumor size (avg, cm)2.092.391.83\<0.001Received chemotherapy no13349.175415865.91 yes1304810155.229331 Unknown8373.811.1ndER ER-65245831.7780.1 ER+19772.712065.67787.50 Unknown93.352.744.5ndHER2 HER2-11642.88546.43135.21 HER2+7226.64323.529331 Unknown8330.65530.12831.8ndHormone therapy No7726.75728.82022.20.28 yes18764.912060.66774.40.03 Unknown248.32110.633.3nd

An independent cohort of 71 invasive breast carcinomas for which Oncotype DX (Genomic Health, Inc.) recurrence scores had been determined were identified from the files of the Department of Pathology and Laboratory Medicine at Strong Memorial Hospital (Rochester, NY). All cases were hormone receptor positive, Her2 negative, and lymph node negative. A representative whole tissue section was cut from each tumor.

This study was approved by the Huntsville Hospital Institutional Review Committee. Archived tumor samples were provided by the Clearview Cancer Institute of Huntsville Alabama and corresponding anonymized patient data was provided via an institutional review board--approved database. An IRB exemption for the use of the tissue samples was granted by the Huntsville Hospital Institutional Review Committee as all patient data were a) anonymized, b) consent was unnecessary, and c) only excess tissue was used.

Tissue arrays were processed as previously described \[[@CR17]\]. TAP antibody was generated in house as previously published. Immunohistochemical staining for TAP was performed on tissue micro-array and whole tissue sections with the method we described previously \[[@CR8]\]. TAP expression was classified as positive or negative, with positive expression defined as any cytoplasmic and/or nuclear staining (Fig. [1](#Fig1){ref-type="fig"}). Commercial antibodies for ER, PR, and HER2 were stained by a commercial service (US Labs Inc). ER and PR were considered positive if at least 1 % of the cells examined exhibited any nuclear staining, and HER2 was scored positive when intense membrane staining in more than 10 % of invasive tumor cells was observed.Fig. 1Invasive ductal carcinoma showing TAP staining positive (**a**), and negative with the positive internal control of normal/benign TDLU (**b**)

In assessing association with outcome, the likelihood ratio test was used in univariate analyses, and the Wald test for multivariate models. All *p* values are presented as two sided, with a value of less than 0.05 being considered significant.

Results {#Sec3}
=======

In the CCI breast cohort of 271 breast carcinoma samples, we observed positive TAP staining in 88 (32 %) and negative staining in 183 (68 %) tumors. Consistent with our previous findings, we found that ER+/PR ± tumors are more likely to exhibit TAP expression than hormone negative tumors (Table [2](#Tab2){ref-type="table"}). Overall, patients with TAP-positive tumors had a lower 5-year recurrence rate (*N* = 271, *p* = 0.002) and better 5-year survival rate (*N* = 264, *p* = 0.010) (Fig. [2a, b](#Fig2){ref-type="fig"}). This positive association with outcome was conserved in all ER-positive tumors, regardless of PR status (5 year recurrence, HR = 0.35, *p* = 0.02, 5 year survival, HR = 0.141, *p* = 0.014) (Fig. [3a, b](#Fig3){ref-type="fig"}). This association was also significant at 10 years post diagnosis (10 year survival HR = 0.21, *p* = 0.0024; 10 year recurrence HR = 0.55, *p* = 0.023). Looking further at the clinically relevant ER+/PR±/Her2- patients, significant associations were also observed (5 year recurrence, HR = 0.17, *p* = 0.035, 5 year survival, HR = \<0.001, *p* = 0.007, *N* = 81). TAP was not prognostic of 5 year recurrence in ER+/HER2+ cases (HR = 0.38 *p* = 0.22, *N* = 57), ER-/HER2-(HR \< 0.01, *p* = 0.23, *N* = 32), or ER-/HER2+ cases (HR = 4.1 *p* = 0.28, *N* = 15). Tumors negative for ER and PR had a non-significant association with 5-year recurrence and survival (Fig. [3c, d](#Fig3){ref-type="fig"}). In triple negative patients the association remained non-significant, though low patient numbers (*N* = 25) makes it difficult to draw conclusions from this subset analysis. Exploratory analysis showed that the association with outcome was even stronger in node-positive patients (5-year recurrence: *N* = 118, *p* = 0.0001; 5-year survival: *N* = 114, *p* = 0.0036), but it was not significant in node-negative patients (5-year recurrence: *N* = 151 and *p* = 0.98; 5-year survival: *N* = 150 and *p* = 0.72) (Fig. [4a-d](#Fig4){ref-type="fig"}). Within PR subsets (ER+/PR- and ER+/PR+), TAP did not have a significant association with recurrence (*p* = 0.102 and 0.098, respectively), though the hazard ratio remained low. Furthermore, TAP was independent of PR when assessed as a multivariable model (data not shown).Table 2TAP and hormone receptor status, patient counts. *P* value for difference between proportion of TAP positive and negative patients determined with a two-proportion z-testTAP-TAP+*P* valueHormone Receptor Negative (ER & PR-)486\<0.001 ER-587\<0.001Hormone Receptor Positive (ER or PR+)12778\<0.001 ER+120770.001HR positive/ HER2-56290.003HR positive/ HER2+31280.35Fig. 2Patients with TAP-positive tumors had a lower 5-year recurrence rate (**a**) and better 5-year survival rate (**b**) than the patients with TAP-negative tumors. TAP-positive tumors are shown via a dotted line, TAP-negative tumors via a solid lineFig. 3In patients with ER+/PR ± positive tumors, TAP positivity was associated with a better 5 year recurrence (**a**) and survival (**b**). In patients with hormone negative (ER-/PR-) tumors TAP showed a non-significant negative association with 5 year recurrence (**c**) and survival (**d**)Fig. 4The association between TAP expression and better prognosis was even stronger in node-positive patients in 5 year recurrence (**a**) and survival (**b**), but was not significant in node-negative patients in 5 year recurrence (**c**) or survival (**d**)

In an exploratory multivariate analysis of TAP status and common clinical variables, TAP was independent of age, stage, hormonal therapy and chemotherapy status with 5 year recurrence as the outcome measurement in all patients (Table [3](#Tab3){ref-type="table"}). TAP was not independent of grade, which suggests that grade and TAP were measuring a shared aspect of cell biology. Indeed, there was a significant negative association between grade and TAP (p \< 0.0001 via chi-square). TAP positive tumors were more likely to represent low grade tumors compared to TAP negative tumors. In patients with ER+/PR ± tumors, TAP expression was independent of stage and age in predicting 5 year recurrence; while in patients with ER+/PR±/Her2- tumors, TAP was not independent of stage (5 year recurrence HR = 0.18, *p* = 0.110). However, only 81 patients were included in this subset. When looking at 5 year survival, TAP expression was independent of age and stage, but not chemotherapy status or tumor grade.Table 3Association of TAP and other clinical variables with outcome using Cox proportional hazard regression. TAP, chemotherapy, grade, stage and age are shown as individual and multivariable models. Variables with a significant association with survival or recurrence are shown in bold5 year survival5 year recurrence5 year recurrence, ER+/PR±HRpNHRpNHRpN**TAP**0.26 (0.08, 0.87)0.012640.35 (0.16, 0.74)0.0022710.35 (0.13, 0.92)0.02197Hormone therapy0.54 (0.25, 1.2)0.122620.68 (0.38, 1.2)0.212611.8 (0.55, 6.2)0.28192**Chemotherapy**4.34 (1.63, 11.6)0.0012622.51 (1.37, 4.6)0.0022632.2 (1, 4.84)0.05193**Grade**4.44 (1.74, 11.3)\<0.0012302.3 (1.34, 3.93)0.0012312.5 (1.24, 5.05)0.007175**Stage**3.35 (1.82, 6.16)\<0.0012642.71 (1.76, 4.17)\<0.0012652.66 (1.47, 4.83)0.001195Age0.98 (0.95, 1.01)0.1932640.98 (0.97, 1)0.0542650.97 (0.94, 1)0.058195**TAP**0.28 (0.08, 0.95)0.042640.38 (0.18, 0.81)0.0122650.37 (0.14, 0.98)0.045195**Stage**3.25 (1.76, 6)\<0.0012.63 (1.71, 4.06)\<0.0012.57 (1.41, 4.69)0.002TAP0.55 (0.16, 1.93)0.352300.54 (0.23, 1.24)0.152310.51 (0.19, 1.39)0.19174**Grade**3.93 (1.52, 10.18)0.0052.05 (1.19, 3.52)0.012.3 (1.15, 4.59)0.018**TAP**0.28 (0.08, 0.94)0.0392640.38 (0.18, 0.82)0.0142650.37 (0.14, 0.98)0.045195Age0.99 (0.96, 1.02)0.370.98 (0.96, 1.01)0.160.97 (0.94, 1.01)0.097**TAP**0.27 (0.08, 0.90)0.0322620.37 (0.17, 0.78)0.00932610.35 (0.13,0.93)0.036192Hormone therapy0.58 (0.27, 1.3)0.170.73 (0.41, 1.3)0.31.77 (0.53, 5.9)0.35**TAP**0.34 (0.1, 1.14)0.0812620.42 (0.2, 0.91)0.0272630.38 (0.14, 1.01)0.052193**Chemotherapy**3.69 (1.37, 9.92)0.012.16 (1.17, 4.01)0.0141.94 (0.87, 4.3)0.1**TAP**0.33 (0.1, 1.13)0.0782620.41 (0.19, 0.89)0.0232630.38 (0.14, 1.03)0.057193**Stage**2.77 (1.42, 5.4)0.0032.44 (1.53, 3.9)02.42 (1.27, 4.61)0.007Chemotherapy2.21 (0.79, 6.17)0.131.35 (0.7, 2.59)0.371.23 (0.53, 2.85)0.63**TAP**0.32 (0.1, 1.1)0.072620.41 (0.19, 0.89)0.0242630.39 (0.15, 1.06)0.065193**Stage**2.8 (1.43, 5.47)0.0032.44 (1.53, 3.9)02.53 (1.34, 4.76)0.004Chemotherapy2.98 (0.89, 10)0.0771.34 (0.61, 2.94)0.470.85 (0.31, 2.32)0.75Age1.02 (0.98, 1.06)0.351 (0.97, 1.03)0.980.97 (0.94, 1.01)0.19

In the study of tumors with a known Oncotype DX recurrence score, TAP was positive in 47 of the 71 tumors (66.2 %), with 29 of 43 (67.4 %) in a low risk group, 16 of 24 (66.7 %) in an intermediate risk group, and 2 of 4 (50 %) in a high risk group (Table [4](#Tab4){ref-type="table"}). There was no association observed between TAP expression and Oncotype DX recurrence risk using a Fisher's exact test (*P* = 0.60).Table 4Comparison of TAP positivity and OncoTypeDx Recurrence scoresRecurrence ScoreTAP +TAP -Total12914432168243224Total472471

The limitation of the study includes relatively small sample size in the CCI breast cohort and Oncotype DX cohort. Ki67 labeling index data and the status of vascular invasion were not available for analysis.

Discussion {#Sec4}
==========

Genes involved in cell proliferation have been shown to comprise a major component of many of the available gene expression signatures used to predict clinical outcome in breast cancer patients \[[@CR11]--[@CR16]\]. TAP has also been implicated in the control of cellular proliferation and other aspects of tumor growth. Researchers demonstrated that vitamin E derivatives can inhibit cell proliferation and colony formation of breast cancer cell lines, and induce apoptosis of the tumor cells \[[@CR18]--[@CR21]\]. As a vitamin E binding protein, TAP can promote vitamin E retention and thus increase its concentration in cells. Our previous studies have demonstrated that TAP can promote vitamin E-induced inhibition of tumor cell proliferation and also regulate tumor cell growth in a vitamin E-independent fashion \[[@CR7]\]. We also showed that TAP is selectively expressed in normal/benign breast luminal epithelium, but not in many other organ systems \[[@CR8]\]. TAP expression is down-regulated at the mRNA and protein levels in several human breast cancer cell lines and in human breast carcinomas compared to a nonmalignant cell line and to normal/benign breast tissue. We extended these observations in current study, which showed that TAP expression is associated with an overall more favorable outcome, both in terms of tumor recurrence and survival rate in breast cancer patients. These findings, taken together, suggest that TAP is a regulator of cell proliferation that can affect breast carcinogenesis and tumor prognosis.

Breast cancer is a heterogeneous group of diseases. The biological features and clinical behavior of individual tumors are frequently different, even within the morphologically low grade, ER+/PR+/Her2- subtype, which is generally considered to be a group with a better prognosis. It is important to identify novel markers which can predict clinical outcomes in this group. We have reported that TAP is co-expressed with ER in the normal/benign breast luminal epithelium of terminal ductal lobular units, where breast carcinogenesis is most likely to be initiated, and that TAP is down regulated in 46 % of ER and PR positive breast carcinomas, indicating that the loss of TAP expression may be associated with the process of hormonal carcinogenesis \[[@CR9]\]. Here we have demonstrated that TAP expression in ER+/PR±/Her2- tumors is associated with a significantly better 5-year recurrence free and survival rate. This finding could be clinically significant in terms of further predicting tumor behaviors of ER+/PR±/Her2- subtype breast carcinomas. Currently, there are few breast carcinogenesis-related oncogenes and tumor suppressor genes that are implicated in the clinical treatment and prognosis. Her2 and p53, the most widely evaluated cancer-related genes, are only altered in approximately 20-25 % of breast carcinomas, primarily in ER/PR negative tumors \[[@CR22]\]. In contrast, TAP is altered in 57 % of breast carcinomas, including 46 % ER/PR+ tumors, thus may serve as a useful complement to existing biomarkers.

OncotypeDX has been used to guide clinical approaches for ER-positive, lymph node-negative breast cancer patients. Even though TAP expression is associated with better clinical outcome in ER-positive tumors, we did not identify any association between TAP expression and OncotypeDX recurrence scores in the additional cohort. This may suggest that TAP expression is associated with a different aspect(s) of tumor biology than is OncotypeDX and may be a useful complement in predicting patient outcome and tumor subclassification. Further study with a larger population of ER+ tumors is needed to help validate these findings.

Several studies have demonstrated a protective effect of vitamin E on the occurrence of several cancers (for review see \[[@CR3]\]). However clinical trials have found little support for dietary supplementation \[[@CR23]\]. The disparity of these results could be due to vitamin E not being cancer preventive at the supra-nutritional level, significant roles for other vitamin E isoforms, such as γ- and δ-tocopherols \[[@CR24]\], or genetic diversity among dietary intervention trial participants contributing to unrecognized heterogeneity in how they utilized vitamin E. Our study found considerable heterogeneity among the tumors in expression of TAP, the vitamin E binding protein, and its significant association with cancer progression. This finding suggests a possible role for TAP in the interplay between vitamin E and cancer progression. Stratification of trial participation by TAP expression may be an interesting and important aspect for the elucidation of how dietary vitamin E supplementation may affect cancer risk and prognosis.

Conclusions {#Sec5}
===========

In summary, we demonstrated that TAP, as a proliferation-related gene in breast carcinogenesis, is associated with a better 5-year clinical outcome, particularly in node-positive and ER+ breast cancer patients. TAP may serve as a prognostic marker, especially in those patients with ER+ low grade breast cancers, and may also serve to stratify studies assessing the role and utility of vitamin E or α-tocopherol supplementation for the prevention of cancer.
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